↳ Topics · 3 papers · 1 editorial
The biological-vs-chronological-age question. Telomere maintenance, senescent-cell biology, and the small family of short peptides that show up in both literatures.
§ About this topic
Longevity research at the molecular level distinguishes biological from chronological age — measured through telomere length, epigenetic clocks, mitochondrial function, and senescent-cell load. A small group of short peptides has been studied across both major mechanism families: telomerase modulators (Khavinson's foundational rodent work, recent human cell-line measurements) and senolytic-adjacent peptides that influence the inflammatory secretome aging cells produce. Mostly preclinical, with a few human cell-line bridges.
↳ Editorial in this topic
↳ Peer-reviewed papers in this topic
“Foundational rodent lifespan-extension work for short bioregulator peptides. SHR-mice cohort showed median-lifespan increases on chronic low-dose administration.”
“Measures telomere length changes in human cell lines following short-peptide exposure, providing a translational anchor for the rodent literature.”
“Surveys therapeutic peptide candidates studied in gerontology contexts, including telomerase modulators and senolytic-adjacent short peptides.”
↳ Related topics
↳ Topic
How short signalling peptides accelerate the body's own tissue-repair machinery — wound closure, tendon healing, gut barrier integrity, vascular regrowth.
↳ Topic
Short peptides that influence BDNF, neurotrophic signalling and stress-resilience pathways. The most clinically-mature area in this library.
↳ Topic
Mitochondrial multitaskers, AMPK signalling, and the gap between published mechanism research and the consumer-marketing narrative.